OCU-400 is under clinical development by Ocugen and currently in Phase II for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase II drugs for Retinitis Pigmentosa (Retinitis) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OCU-400’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OCU-400 overview

OCU-400 is under development for the treatment of inherited degenerative retinal diseases (IRDs) such as NR2E3, CEP290, PDE6B and RHO mutation-associated recessive retinal degeneration, Leber Congenital Amaurosis (LCA), Bardet-Biedl Syndrome (BBS), enhanced S-cone syndrome and rhodopsin mutations associated retinitis pigmentosa and other retinal degenerations. It is administered as sub-retinal injection. The therapeutic candidate is an adeno-associated virus serotype 5 capsid containing the gene for human nuclear hormone receptor NR2E3. It is developed based on modifier gene therapy platform. It acts by targeting centrosomal protein of 290 kDa (CEP290) and Rhodopsin

Ocugen overview

Ocugen Is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment. It is investigating OCU-400 against NR2E3, RHO, CEP290, and PDE6B mutation-associated retinal degeneration; and OCU-410 targeting dry age-related macular degeneration. The company is developing OCU200 drugs to treat diabetic macular edema, diabetic retinopathy, and wet-age-related macular degeneration. Ocugen is also investing OCU410ST for stargardt orphan disease. It utilizes a modified gene therapy platform to develop its products. The company operates in Ireland and the US. Ocugen is headquartered in Malvern, Pennsylvania, the US.

For a complete picture of OCU-400’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.